Evidence map›Paper›PMID 36376455›Full record

ArticleScientific reports2022

Proline, hydroxyproline, and pyrrolidone carboxylic acid derivatives as highly efficient but reversible transdermal permeation enhancers.

Monika Kopečná, Miloslav Macháček, Jaroslav Roh, Kateřina Vávrová

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Monika KopečnáSkin Barrier Research Group, Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
Miloslav MacháčekDepartment of Biochemical Sciences, Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
Jaroslav RohDepartment of Organic and Bioorganic Chemistry, Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005, Hradec Králové, Czech Republic.
Kateřina VávrováSkin Barrier Research Group, Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 50005, Hradec Králové, Czech Republic. katerina.vavrova@faf.cuni.cz.
Charles University · CZ

Funding

European Union CZ.02.1.01/0.0/0.0/16_019/0000841Grantová Agentura České Republiky 19-09600S
6 · The paper itself

Abstract

Overcoming the skin barrier properties efficiently, temporarily, and safely for successful transdermal drug delivery remains a challenge. We synthesized three series of potential skin permeation enhancers derived from natural amino acid derivatives proline, 4-hydroxyproline, and pyrrolidone carboxylic acid, which is a component of natural moisturizing factor. Permeation studies using in vitro human skin identified dodecyl prolinates with N-acetyl, propionyl, and butyryl chains (Pro2, Pro3, and Pro4, respectively) as potent enhancers for model drugs theophylline and diclofenac. The proline derivatives were generally more active than 4-hydroxyprolines and pyrrolidone carboxylic acid derivatives. Pro2-4 had acceptable in vitro toxicities on 3T3 fibroblast and HaCaT cell lines with IC

Indexed as

ProlineSkin AbsorptionAdministration, CutaneousCarboxylic AcidsHumansHydroxyprolineOrganic ChemicalsPermeabilityPharmaceutical PreparationsPyrrolidinonesSkinCarboxylic AcidsHydroxyprolineOrganic ChemicalsPharmaceutical PreparationsProlinePyrrolidinones

Identifiers

PMID36376455
PMCPMC9663686
OpenAlexW4308966110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.